Abstract
Widespread use of thrombolytic agents in a variety of settings has highlighted the need for measures of safety and efficacy. Previously used laboratory parameters, such as decreasing levels of fibrinogen and increasing levels of fibrin(ogen) degradation products (FDPs), have failed to correlate consistently with hemorrhagic events and have not yet been useful in predicting patients at risk for bleeding. Although the bleeding time (BT) has been considered primarily to reflect platelet function, it also reflects the interaction of platelets with vessel wall and coagulation pathways. Recently, the BT has been considered as a potential predictor of clinical bleeding during thrombolysis. The BT, as a measure of in vivo hemostatic competence, may be particularly well-suited for this application. Serial BTs during thrombolytic therapy may provide valuable information regarding safety and efficacy, but further studies are needed to confirm preliminary findings.
References
Jan 1, 1990·American Heart Journal·D R Hirsch, S Z Goldhaber
Jun 1, 1987·The Journal of Clinical Investigation·J Loscalzo, D E Vaughan
Sep 1, 1989·Circulation·L W GimpleD Collen
Nov 1, 1989·Circulation·D C StumpD Collen
Mar 1, 1989·Circulation·M HerasV Fuster
Feb 1, 1989·Chest·A G FennertyJ Hirsh
May 15, 1989·The American Journal of Cardiology·B BrennerV J Marder
Jun 1, 1987·Circulation·D E VaughanJ Loscalzo
Jan 1, 1988·Journal of the American College of Cardiology·A K RaoM L Terrin
Jun 1, 1988·Journal of the American College of Cardiology·D E VaughanJ Loscalzo
Jun 1, 1986·Journal of the American College of Cardiology·A S LewW Ganz
Jul 1, 1973·The Journal of Clinical Investigation·S NiewiarowskiP Gillies
Jul 27, 1972·The New England Journal of Medicine·L A Harker, S J Slichter
Aug 1, 1984·The American Journal of Medicine·S E Lind
Aug 15, 1982·Thrombosis Research·L CaprinoL Morelli